← Back to Search

Monoclonal Antibodies

Humanized 3F8 Bispecific Antibody for Neuroblastoma

Phase 1 & 2
Waitlist Available
Research Sponsored by Y-mAbs Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 1 through 28 in cycle 1
Awards & highlights

Study Summary

This study is evaluating whether a new drug may be safe for individuals with cancer.

Eligible Conditions
  • Neuroblastoma
  • Osteosarcoma
  • Solid Tumor Cancers

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 1 through 28 in cycle 1
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 1 through 28 in cycle 1 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose Limiting Toxicities (DLTs) Phase I

Trial Design

1Treatment groups
Experimental Treatment
Group I: Hu3F8-BsAbExperimental Treatment2 Interventions
Phase I Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle. In cycle 1, blood is drawn for PK studies.Phase II Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle.

Find a Location

Who is running the clinical trial?

Y-mAbs TherapeuticsLead Sponsor
25 Previous Clinical Trials
1,545 Total Patients Enrolled
12 Trials studying Neuroblastoma
1,180 Patients Enrolled for Neuroblastoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Expert Opinion on Emerging DrugsJournal
An Update on Emerging Drugs in Osteosarcoma: Towards Tailored Therapies?
Hattinger, Claudia Maria, Maria Pia Patrizio, Federica Magagnoli, Silvia Luppi, and Massimo Serra. 2019. “An Update on Emerging Drugs in Osteosarcoma: Towards Tailored Therapies?”. Expert Opinion on Emerging Drugs. Informa UK Limited. doi:10.1080/14728214.2019.1654455.
clinicaltrials.govStudy
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
2019. "Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03860207.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top